| Outcome | Probability | Yes Bid | Yes Ask | 24h Change | Volume | |
|---|---|---|---|---|---|---|
| Before July 2027 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before October 2027 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before 2028 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
This market asks when the U.S. Food and Drug Administration will approve Intellia Therapeutics' lonvo-z, a clinical-stage gene‑editing therapeutic candidate. The timing matters for patient access, corporate value, and precedent for in vivo gene‑editing regulation.
Lonvo-z is Intellia's investigational CRISPR‑based therapy advancing through clinical development and regulatory interaction with the FDA. Approval requires a marketing application that demonstrates adequate safety, efficacy, and manufacturing quality; the company and regulator may exchange data, requests, and inspections before a final decision. Regulatory review can be affected by the strength of pivotal trial data, manufacturing readiness, and any agency requests for additional information or studies.
Market prices reflect traders' aggregated expectations about timing based on public data, filings, and news— they are not guarantees of outcome. Use official FDA filings, company disclosures, and regulatory notices for definitive status updates.
Approval typically follows submission of a marketing application (e.g., a BLA) and FDA acceptance for review, which may include designation decisions (priority/accelerated), a review period with a target action date, facility inspections, and possible advisory committee input or requests for more data.
Watch for a formal marketing application submission and acceptance notice, FDA review designations or a target action date, publication or company release of pivotal trial results, announcements of advisory committee meetings or facility inspection outcomes, and any FDA communications such as complete response letters.
Clear, robust efficacy with a favorable safety profile can support expedited review pathways and a smoother approval, while ambiguous efficacy, safety signals, or small sample sizes often prompt requests for more data or additional studies, delaying approval.
Manufacturing issues are a common source of delay: inadequate process validation, quality control problems, or failed facility inspections can lead the FDA to withhold approval until deficiencies are corrected and evidence of consistent product quality is provided.
Key actors include Intellia (the sponsor), FDA review divisions and advisory committees, contract manufacturers and quality teams, clinical investigators generating pivotal data, and occasionally external bodies whose recommendations or public input can influence regulatory decisions.